Cargando…
Bruton’s tyrosine kinase inhibition reduces disease severity in a model of secondary progressive autoimmune demyelination
Bruton’s tyrosine kinase (BTK) is an emerging target in multiple sclerosis (MS). Alongside its role in B cell receptor signaling and B cell development, BTK regulates myeloid cell activation and inflammatory responses. Here we demonstrate efficacy of BTK inhibition in a model of secondary progressiv...
Autores principales: | Evonuk, Kirsten Scarlett, Wang, Sen, Mattie, Josh, Cracchiolo, C. J., Mager, Reine, Ferenčić, Željko, Sprague, Ethan, Carrier, Brandon, Schofield, Kai, Martinez, Evelyn, Stewart, Zachary, Petrosino, Tara, Johnson, Gregory Andrew, Yusuf, Isharat, Plaisted, Warren, Naiman, Zachary, Delp, Timothy, Carter, Laura, Marušić, Suzana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337138/ https://www.ncbi.nlm.nih.gov/pubmed/37438842 http://dx.doi.org/10.1186/s40478-023-01614-w |
Ejemplares similares
-
Inhibition of Bruton’s tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease
por: Torke, Sebastian, et al.
Publicado: (2020) -
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
por: Evonuk, Kirsten S., et al.
Publicado: (2016) -
Expression of Bruton´s tyrosine kinase in different type of brain lesions of multiple sclerosis patients and during experimental demyelination
por: Elkjaer, Maria L., et al.
Publicado: (2023) -
Bruton's Agammaglobulinemia and COVID-19
por: Hovey, Justin G, et al.
Publicado: (2020) -
Bruton's tyrosine kinase: oncotarget in myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2012)